Biomerica, Inc. BMRA

Biomerica reported its fiscal 2026 year-end financial results including revenue, net loss and operational metrics. Year-end results supply performance data that can shift near-term investor views and valuation.

Biomerica, Inc. (BMRA) announces $2.23 million financing. $2.23 million financing supplies capital that supports operations and financial position with moderate but non-transformative effects.

Biomerica secures $1.75 million CDMO master services agreement for IVD diagnostic development. $1.75 million CDMO agreement adds contract revenue and supports Biomerica diagnostic development efforts.

Biomerica’s inFoods® IBS data accepted for presentation at Digestive Disease Week 2026. Presentation acceptance at major gastroenterology conference validates inFoods® IBS progress and may moderately enhance market sentiment and competitive positioning.

Biomerica, Inc. announces Medicare Administrative Contractor confirmation of individual claim review for inFoods® IBS test, opening scalable Medicare commercialization pathway. Medicare claim review confirmation unlocks scalable commercialization for inFoods® IBS, potentially driving significant revenue growth and market expansion.

Biomerica, Inc. (BMRA) launched its inFoods® IBS diagnostic product in Canada through partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs. Launching inFoods® IBS in Canada expands Biomerica's market reach and revenue potential via strategic partnerships.

Biomerica, Inc. (BMRA) reported third quarter fiscal 2026 financial results. Quarterly financial results disclosure influences BMRA's financial performance and investor sentiment.

Biomerica, Inc. (BMRA) received its first commercial order for the Hp Detect™ H. pylori diagnostic test from one of Europe's largest clinical laboratory chains. First commercial order from a major European lab chain marks a key product validation and potential revenue expansion into international markets.

Biomerica, Inc. (BMRA) secured MHRA registration for its hp+detect™ product, enabling immediate commercial sales throughout Great Britain. MHRA registration opens the UK market for hp+detect™, providing Biomerica significant revenue potential and international expansion.

Biomerica reports real-world data showing nearly 60% of IBS patients achieved clinically meaningful pain reduction and 68% bloating reduction with inFoods® IBS Therapy. Real-world efficacy data for inFoods® IBS Therapy demonstrates strong clinical benefits, likely boosting product adoption, revenue potential, and stock performance.

Vietnam approves Biomerica’s EZ Detect™ colorectal cancer screening test for nationwide distribution, enabling broader market access and potential revenue growth in the region. Regulatory approval for nationwide distribution in Vietnam represents a major international expansion for Biomerica's key diagnostic product, likely boosting revenue and market sentiment.

Biomerica, Inc. (BMRA) reported its financial results for the second quarter of fiscal 2026, highlighting key metrics such as revenue growth and net income. The company experienced an increase in sales driven by demand for its diagnostic products. Management expressed optimism about future growth prospects and ongoing product development initiatives. The report also included updates on strategic partnerships and market expansion efforts, indicating a positive outlook for the remainder of the fiscal year. The financial results indicate moderate growth and positive developments, which may influence investor sentiment and operational performance.

Biomerica, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has established a Medicare payment rate of $300 for its inFoods® IBS test. This test is designed to help manage Irritable Bowel Syndrome (IBS) by identifying food sensitivities. The new payment rate is expected to enhance patient access to the test and support Biomerica's growth in the IBS market. The establishment of a Medicare payment rate significantly enhances the market potential and accessibility of Biomerica's inFoods® IBS test, likely impacting future revenue and investor sentiment.

The Egyptian Drug Authority has authorized Biomerica, Inc.'s complete screening test portfolio, which includes tests for various medical conditions. This approval allows Biomerica to expand its market presence in Egypt, potentially increasing revenue and enhancing its competitive position in the diagnostics sector. The authorization of the complete screening test portfolio is a significant regulatory achievement that can enhance market opportunities and revenue growth for Biomerica.

Biomerica, Inc.'s inFoods® IBS product has been highlighted in Biotherapeutics Quarterly, a publication by Henry Schein, showcasing a new precision approach for treating Irritable Bowel Syndrome (IBS). This recognition emphasizes the innovative nature of Biomerica's product in addressing IBS, potentially enhancing its market visibility and credibility in the healthcare sector. The feature in a reputable publication indicates significant recognition and potential market impact for Biomerica's IBS treatment approach.

Biomerica, Inc. is expanding its contract development and manufacturing services to address the increasing demand in the market. This strategic move aims to enhance the company's capabilities and support its growth in the diagnostics and healthcare sectors. The expansion is expected to position Biomerica favorably amidst rising market needs. The expansion of contract development and manufacturing services is a significant strategic move that could enhance Biomerica's market position and financial performance.

Biomerica, Inc. has entered a strategic partnership with Henry Schein, Inc., enhancing Henry Schein's diagnostic capabilities and expanding its product offerings. This collaboration is expected to strengthen Henry Schein's position in the healthcare market and improve Biomerica's visibility and growth potential. The deal aligns with Henry Schein's ambitions to innovate in diagnostics, potentially leading to increased market share and revenue for both companies. The partnership is a significant strategic move that could enhance market positioning and investor sentiment for both companies.

Biomerica, Inc. has entered into a marketing services agreement with Henry Schein for the promotion of its inFoods® IBS Test in the U.S. This collaboration aims to enhance the distribution and visibility of the IBS test, which is designed to help manage symptoms of irritable bowel syndrome. The partnership is expected to leverage Henry Schein's extensive network and expertise in the healthcare market, potentially increasing Biomerica's market reach and sales. The agreement with Henry Schein is a significant strategic move that could enhance Biomerica's market presence and sales performance.

Biomerica, Inc. (BMRA) reported its financial results for the first quarter of fiscal 2026, highlighting a revenue increase driven by strong demand for its diagnostic products. The company noted improvements in gross margins and a reduction in operating losses compared to the previous year. Management expressed optimism about future growth prospects, citing ongoing product development and expansion into new markets. The results reflect the company's strategic focus on innovation and enhancing its product portfolio. The financial results indicate moderate improvements in performance and growth potential, but the overall impact on the company's trajectory remains limited.

Gary Huff, the former CEO of LabCorp Diagnostics, has been appointed to the Board of Directors of Biomerica, Inc. This strategic move is expected to enhance Biomerica's leadership and expertise in the diagnostics sector, potentially driving future growth and innovation. Huff's extensive experience in diagnostics could significantly influence Biomerica's strategic direction and market positioning.

Biomerica, Inc. has launched the AI-Backed inFoods® IBS Trigger Food Navigator, designed to assist in personalized therapy for Irritable Bowel Syndrome (IBS) patients. This innovative tool aims to improve patient outcomes by identifying specific food triggers, thereby enhancing the management of IBS symptoms. The launch reflects Biomerica's commitment to leveraging technology in healthcare to support individualized treatment plans. The introduction of an AI-driven tool for IBS management represents a significant strategic move that could enhance patient outcomes and strengthen Biomerica's market position.

The United Arab Emirates Ministry of Health and Prevention has approved Biomerica, Inc.'s Fortel® Kidney Test for home use. This approval allows patients to monitor their kidney health conveniently at home, potentially increasing the test's market reach and accessibility. The Fortel® test is designed to provide timely information about kidney function, which is crucial for early detection of kidney-related issues. Approval for home use of the Fortel® Kidney Test represents a significant strategic move that could enhance market penetration and investor sentiment.

Biomerica, Inc. (BMRA) reported its fiscal 2025 year-end results, highlighting significant growth in revenue and advancements in product development. The company achieved a notable increase in sales driven by its innovative diagnostic products. Additionally, Biomerica outlined its strategic plans for future growth, focusing on expanding its market presence and enhancing its product offerings. The financial results reflect a positive trajectory, positioning the company favorably within the competitive landscape. The reported growth in revenue and strategic plans for expansion indicate a significant impact on future performance.

Biomerica, Inc. has received approval in the United Arab Emirates for its at-home ulcer test, expanding its product offerings in the diagnostics market. This approval allows the company to cater to a growing demand for convenient home testing solutions, potentially enhancing its market presence and revenue streams. The approval for the at-home ulcer test represents a significant strategic move that could enhance Biomerica's competitive positioning and market reach.

The United Arab Emirates Ministry of Health and Prevention has approved Biomerica, Inc.'s Fortel® Ulcer Test for home use, allowing patients to conduct tests in the comfort of their homes. This approval is expected to enhance patient accessibility to ulcer testing and potentially increase the market reach of Biomerica's products. The Fortel® test is designed to provide quick and reliable results, which could improve patient outcomes and streamline healthcare processes. Approval for home use of the Fortel® Ulcer Test represents a significant strategic move that could enhance market penetration and investor sentiment.

Biomerica, Inc. (BMRA) has been identified as one of the most active stocks in the market, indicating heightened trading activity and interest among investors. This surge in activity may reflect recent developments or market sentiment surrounding the company, potentially influencing its stock performance and investor engagement. Increased trading activity suggests a moderately noticeable influence on market sentiment and investor interest.

Biomerica, Inc. announced that the American Medical Association has issued a CPT® Proprietary Laboratory Analysis (PLA) code for its inFoods® IBS test, effective October 1, 2025. This code will facilitate claims submission to Medicare and private insurers, enhancing patient access to the test, which identifies food triggers for IBS symptoms. The PLA code is a significant milestone in Biomerica's commercialization strategy, aiming to improve insurance reimbursement and support personalized dietary therapy for IBS patients. The inFoods® IBS test has shown clinical validation in trials, demonstrating its effectiveness in reducing IBS symptoms. The issuance of the PLA code is a significant strategic move that is expected to enhance insurance reimbursement and expand patient access, potentially altering the company's trajectory.

Biomerica, Inc. has appointed Scott Madel as Chief Commercial Officer, bringing over 20 years of experience in laboratory testing and clinical diagnostics. Madel previously led Boston Heart Diagnostics and Genova Diagnostics, achieving significant revenue growth and successful organizational turnarounds. In his new role, he will focus on expanding commercialization and revenue growth for inFoods® IBS, a diagnostic-guided therapy for chronic GI conditions. The inFoods® IBS test has shown promising clinical results, demonstrating efficacy in reducing symptoms for patients with IBS. Biomerica aims to enhance patient outcomes and reduce treatment costs through this innovative solution. The appointment of a seasoned executive and the focus on a promising product launch are likely to significantly impact Biomerica's future performance and market position.

Biomerica, Inc. has appointed Eric B. Chin to its Board of Directors and as Chairperson of the Audit Committee, effective June 4, 2025. Chin, who has over 20 years of financial experience in healthcare, currently serves as CFO of Akido Labs and has a history of executive roles in various organizations. His appointment is expected to enhance Biomerica's corporate governance and financial oversight as the company focuses on scaling its commercialization efforts. Chin replaces Cathy Coste, who resigned without any disagreement with the company. Chin's extensive financial background and leadership roles may moderately influence Biomerica's financial performance and governance.

Biomerica, Inc. announced the publication of a pivotal clinical trial in the June 2025 issue of Gastroenterology, demonstrating the effectiveness of its inFoods® IBS test for managing Irritable Bowel Syndrome (IBS). The study showed significant symptom improvement, particularly for IBS-M patients, who currently lack FDA-approved drug treatments. The trial involved 238 patients across eight U.S. academic centers and highlighted that 59.6% of the treatment group achieved abdominal pain reduction compared to 42.2% in the control group. The inFoods IBS test identifies food triggers that provoke IBS symptoms, offering a personalized, non-drug treatment approach. CEO Zack Irani-Cohen emphasized the study's significance in precision nutrition for IBS management. The publication of significant clinical trial results could lead to increased adoption of Biomerica's inFoods IBS test, impacting future sales and market positioning.